Bank Of New York Mellon Corp Allovir, Inc. Transaction History
Bank Of New York Mellon Corp
- $521 Trillion
- Q1 2024
A detailed history of Bank Of New York Mellon Corp transactions in Allovir, Inc. stock. As of the latest transaction made, Bank Of New York Mellon Corp holds 159,423 shares of ALVR stock, worth $121,161. This represents 0.0% of its overall portfolio holdings.
Number of Shares
159,423
Previous 204,974
22.22%
Holding current value
$121,161
Previous $139 Million
13.63%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ALVR
# of Institutions
80Shares Held
49.1MCall Options Held
385KPut Options Held
2.3K-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$8.58 Million0.24% of portfolio
-
Artal Group S.A. Luxembourg, N46.6MShares$5.01 Million0.27% of portfolio
-
Octagon Capital Advisors LP New York, NY4.2MShares$3.19 Million0.5% of portfolio
-
Black Rock Inc. New York, NY3.39MShares$2.57 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.94MShares$2.24 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $70.7M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...